Children with antineutrophil cytoplasmic antibody–associated vasculitis had similar remissions rates with rituximab and ...

Granulomatosis with polyangiitis (GPA), or Wegener’s granulomatosis ... pain in joints or muscles, and rash on the skin. It can be challenging to get a vasculitis diagnosis, especially when the ...

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...

Rashes and other skin changes may be a sign of COVID-19, in addition to classic symptoms like a cough, fatigue, fever, and sore throat. Some people develop a COVID rash, which can appear on body ...

It might be used, for example, as part of initial treatment for severe GPA-type vasculitis (granulomatosis with polyangiitis vasculitis), along ... mild hair loss, rash, fatigue, or headache. Although ...

has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated vasculitis that can result in damage to ...

An exanthem is any eruptive skin rash that may be associated with fever or other systemic symptoms. Causes include infectious pathogens, medication reactions and, occasionally, a combination of both.

Muscle weakness and a skin rash are the main symptoms. Dermatomyositis isn't a common condition. Fewer than 5,000 people in the United States have it. It’s most common in two age groups ...

It is most common in children, but it can also affect adults. The main symptom of fifth disease is a rash that often appears on the cheeks. It can be bright red on lighter skin tones and not as ...

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union as an add-on treatment for adults with eosinophilic granulomatosis ...

3 1. Furuta S, et al. Update on eosinophilic granulomatosis with polyangiitis. Allergol Int. 2019;68:430-436. 2. American Partnership for Eosinophilic Disorders. Eosinophilic Granulomatosis with ...

New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral ...